Publication:
GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility

Simple item page
dc.contributor.authorTorrens-Mas, Margalida
dc.contributor.authorPerelló-Reus, Catalina M
dc.contributor.authorTrias-Ferrer, Neus
dc.contributor.authorIbargüen-González, Lesly
dc.contributor.authorCrespí, Catalina
dc.contributor.authorGalmes-Panades, Aina Maria
dc.contributor.authorNavas-Enamorado, Cayetano
dc.contributor.authorSanchez-Polo, Andrés
dc.contributor.authorPierola Lopetegui, Javier
dc.contributor.authorMasmiquel, Lluis
dc.contributor.authorSocias, Lorenzo
dc.contributor.authorBarceló, Carles
dc.contributor.authorGonzalez-Freire, Marta
dc.date.accessioned2024-10-04T13:22:51Z
dc.date.available2024-10-04T13:22:51Z
dc.date.issued2022-07-22
dc.description.abstractCoronavirus disease 19 (COVID-19) is a persistent global pandemic with a very heterogeneous disease presentation ranging from a mild disease to dismal prognosis. Early detection of sensitivity and severity of COVID-19 is essential for the development of new treatments. In the present study, we measured the levels of circulating growth differentiation factor 15 (GDF15) and angiotensin-converting enzyme 2 (ACE2) in plasma of severity-stratified COVID-19 patients and uninfected control patients and characterized the in vitro effects and cohort frequency of ACE2 SNPs. Our results show that while circulating GDF15 and ACE2 stratify COVID-19 patients according to disease severity, ACE2 missense SNPs constitute a risk factor linked to infection susceptibility.en
dc.description.sponsorshipMiguel Servet program. Instituto de Salud Carlos III (ISCIII), Madrid; Fondo extraordinario COVID-ISCIII. Fundació LaMarato TV3. Margalida Comas Program. Comunidad Autonoma de las Islas Baleares. FOLIUM fellowship program. Impost turisme sostenible/Govern de les Illes Balears. TECH fellowship program, Impost turisme sostenible/Govern de les Illes Balears. LIBERI 2022 program.es_ES
dc.format.page942951es_ES
dc.format.volume12es_ES
dc.identifier.citationTorrens-Mas M, Perelló-Reus CM, Trias-Ferrer N, Ibargüen- González L, Crespí C, Galmes-Panades AM, et al. GDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibility. Front Cell Infect Microbiol. 2022 Jul 22;12:942951.en
dc.identifier.doi10.3389/fcimb.2022.942951
dc.identifier.e-issn2235-2988es_ES
dc.identifier.journalFrontiers in cellular and infection microbiologyes_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/18040
dc.identifier.pubmedID35937703es_ES
dc.identifier.puiL2018441801
dc.identifier.scopus2-s2.0-85135551051
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23440
dc.identifier.wos837144000001
dc.language.isoengen
dc.publisherFrontiers Media
dc.relation.publisherversionhttps://doi.org/10.3389/fcimb.2022.942951en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.decsPeptidil-Dipeptidasa A*
dc.subject.decsFactor 15 de Diferenciación de Crecimiento*
dc.subject.decsHumanos*
dc.subject.decsSARS-CoV-2*
dc.subject.decsEnzima Convertidora de Angiotensina 2*
dc.subject.decsCOVID-19*
dc.subject.decsMutación*
dc.subject.meshMutation*
dc.subject.meshAngiotensin-Converting Enzyme 2*
dc.subject.meshSARS-CoV-2*
dc.subject.meshHumans*
dc.subject.meshPeptidyl-Dipeptidase A*
dc.subject.meshCOVID-19*
dc.subject.meshGrowth Differentiation Factor 15*
dc.titleGDF15 and ACE2 stratify COVID-19 patients according to severity while ACE2 mutations increase infection susceptibilityen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)